This category page covers biotechnology and pharmaceutical companies developing therapies targeting circadian rhythm dysfunction in Parkinson's disease. Circadian disruption is a prominent non-motor symptom in PD, often manifesting years before motor diagnosis, and contributes to sleep-wake fragmentation, motor fluctuations, autonomic dysfunction, and accelerated disease progression[@bordet2017].
The main therapeutic targets in this space include:
Mechanism: Selective melatonin MT1/MT2 receptor agonist (tasimelteon)
Clinical Stage: Approved (Non-24-Hour Rhythm Disorder); Investigating in PD
This category page covers biotechnology and pharmaceutical companies developing therapies targeting circadian rhythm dysfunction in Parkinson's disease. Circadian disruption is a prominent non-motor symptom in PD, often manifesting years before motor diagnosis, and contributes to sleep-wake fragmentation, motor fluctuations, autonomic dysfunction, and accelerated disease progression[@bordet2017].
The main therapeutic targets in this space include:
Mechanism: Selective melatonin MT1/MT2 receptor agonist (tasimelteon)
Clinical Stage: Approved (Non-24-Hour Rhythm Disorder); Investigating in PD
Background: Vanda Pharmaceuticals developed tasimelteon (Hetlioz), the first FDA-approved medication for non-24-hour sleep-wake disorder, a condition affecting blind individuals. Tasimelteon is a dual melatonin receptor agonist that binds to both MT1 and MT2 receptors, helping to synchronize the circadian clock. Vanda has explored tasimelteon's potential in PD circadian dysfunction, where melatonin levels are significantly reduced and circadian amplitude is diminished[@vanda2024].
Key Science:
Mechanism: Dual orexin OX1/OX2 receptor antagonist (daridorexant/Quviviq)
Clinical Stage: Approved (Insomnia); Investigating in PD
Background: Idorsia's daridorexant is a dual orexin receptor antagonist approved for insomnia disorder. While not specifically developed for PD, orexin antagonists may have therapeutic potential in PD by normalizing sleep architecture and potentially influencing alpha-synuclein clearance. Idorsia has explored ACT-462206 for sleep disorders in neurodegenerative disease.
Key Science:
Mechanism: Dual orexin OX1/OX2 receptor antagonist (lemborexant/Dayvigo)
Clinical Stage: Approved (Insomnia); Investigating in PD
Background: Eisai developed lemborexant (Dayvigo), a dual orexin receptor antagonist approved for insomnia disorder. Lemborexant is being investigated in PD patients with sleep disturbances. The orexin system is dysregulated in PD, contributing to sleep-wake fragmentation and potentially accelerating neurodegeneration.
Key Science:
Mechanism: Melatonin MT1/MT2 receptor agonist (piromelatine/TH-102)
Clinical Stage: Phase 2/3
Background: Neurim Pharmaceuticals specializes in circadian rhythm therapeutics. Piromelatine is a novel melatonin receptor agonist with additional serotonin 5-HT2C antagonist activity. It is being developed for neurodegenerative diseases with comorbid sleep disturbances. Clinical trials have evaluated piromelatine in AD and PD patients with circadian dysfunction.
Key Science:
Mechanism: Bright light therapy devices (Somneo, GoLite)
Clinical Stage: Clinical use (non-pharmacological)
Background: Philips has developed light therapy devices for circadian entrainment. Bright light therapy (10,000 lux) in the morning helps strengthen circadian amplitude through the retinohypothalamic tract. Multiple clinical trials have evaluated bright light therapy in PD, demonstrating improvements in sleep quality and motor function.
Key Science:
Mechanism: Near-infrared photobiomodulation (810nm) via intranasal and transcranial delivery
Clinical Stage: Phase 2 (AD/PD)
Background: Vielight develops non-invasive neurostimulation devices using photobiomodulation. Their Neuro Alpha device delivers near-infrared light to deep brain structures including the hypothalamus. PBM may strengthen circadian clock function by enhancing mitochondrial function in SCN neurons.
Key Science:
Mechanism: REV-ERB agonist / SIRT1 activator programs
Clinical Stage: Discovery
Background: Takeda has explored circadian clock modulators including REV-ERB agonists and SIRT1 activators as potential treatments for neurodegenerative diseases. The nuclear receptors REV-ERBα and REV-ERBβ are key components of the clock feedback loop, and their agonism can reinforce BMAL1 expression and strengthen circadian amplitude.
Key Science:
Mechanism: OX1/OX2 receptor antagonists for PD sleep disorders
Clinical Stage: Discovery
Background: AbbVie has orexin antagonist programs in discovery for sleep disorders in neurodegenerative diseases. The company leverages its neuroscience expertise to develop novel approaches for PD non-motor symptoms.
| Target | Drug/Program | Company | Mechanism | Stage |
|--------|-------------|---------|-----------|-------|
| Melatonin MT1/MT2 | Tasimelteon | Vanda | Agonist — restores nocturnal signaling | Approved (Non-24); PD Phase 2 |
| Melatonin MT1/MT2 | Piromelatine | Neurim | Agonist — sleep + neuroprotection | Phase 2/3 |
| Orexin OX1/OX2 | Daridorexant | Idorsia | Antagonist — sleep normalization | Approved; PD Phase 2 |
| Orexin OX1/OX2 | Lemborexant | Eisai | Antagonist — sleep normalization | Approved; PD Phase 2 |
| Light therapy | Somneo, GoLite | Philips | Zeitgeber — strengthens SCN | Clinical use |
| Near-infrared PBM | Neuro Alpha | Vielight | SCN stimulation | Phase 2 |
| REV-ERB | SR9009 analogs | Takeda | Agonist — reinforces BMAL1 | Discovery |
| SIRT1 | NAD+ boosters | Various | Activator — metabolic coupling | Research |
Melatonin (N-acetyl-5-methoxytryptamine) is the primary hormone of darkness, secreted by the pineal gland during the biological night. In PD, melatonin levels decline dramatically — even before clinical symptoms appear — and this decline correlates with circadian rhythm disruption. Melatonin acts through two G-protein coupled receptors (MT1 and MT2) that are widely distributed in the suprachiasmatic nucleus, substantia nigra, and cortex. Beyond sleep promotion, melatonin exerts antioxidant, anti-inflammatory, and neuroprotective effects relevant to PD pathophysiology.
The orexin (hypocretin) system consists of hypothalamic neurons producing orexin-A and orexin-B peptides that signal through OX1 and OX2 receptors to promote wakefulness. In PD, orexin neuron function is disrupted, leading to sleep-wake fragmentation. Additionally, LRRK2 G2019S has been shown to directly phosphorylate PER2 protein, disrupting the core clock machinery. Dual orexin receptor antagonists (DORAs) like lemborexant and daridorexant promote sleep by blocking orexin signaling.
A key mechanistic link between PD and circadian dysfunction involves LRRK2-mediated PER2 phosphorylation. Cai et al. demonstrated that LRRK2 G2019S directly phosphorylates PER2, disrupting nuclear feedback loops and altering period length. This provides a molecular basis for circadian dysfunction in LRRK2-associated PD and suggests targeting the clock machinery may have disease-modifying potential.
Light is the primary zeitgeber (time-giver) that entrains the suprachiasmatic nucleus to the 24-hour day. In PD patients, reduced visual acuity, limited outdoor exposure, and autonomic dysfunction lead to inadequate light input, weakening circadian entrainment. Bright light therapy (morning exposure to 10,000 lux white light) strengthens SCN function, improves sleep-wake consolidation, and has been shown to improve motor function in PD patients.
| Trial ID | Intervention | Status | Outcome |
|----------|--------------|--------|---------|
| NCT03829583 | Bright light therapy (10,000 lux) | Completed | Improved sleep quality and motor function |
| NCT04810069 | Melatonin supplementation | Ongoing | Circadian rhythm stability |
| NCT05117086 | Lemborexant | Completed | Sleep improvement in PD |
| NCT05274854 | Combined light + exercise | Recruiting | Circadian alignment |
| NCT04567810 | Circadian entrainment (RBD) | Active | Sleep-wake consolidation |
The circadian/sleep therapeutic field for PD is emerging, with no FDA-approved treatments specifically targeting circadian dysfunction in PD. Key differentiators:
| Approach | Advantages | Risks |
|----------|------------|-------|
| Melatonin agonists | Well-tolerated, addresses multiple pathways (sleep + neuroprotection) | Modest efficacy for sleep alone |
| Orexin antagonists | Direct sleep-wake normalization, approved for insomnia | May not address underlying clock dysfunction |
| Photobiomodulation | Non-pharmacological, no drug interactions | Device-based, variable delivery |
| REV-ERB/SIRT1 | Targets core clock machinery, disease-modifying potential | Early stage, unclear translation |
| Light therapy | Safe, evidence-based, low cost | Compliance challenges |